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Abstract
Objective To investigate the incremental cost effectiveness of two dose
human papillomavirus vaccination and of additionally giving a third dose.
Design Cost effectiveness study based on a transmission dynamic
model of human papillomavirus vaccination. Two dose schedules for
bivalent or quadrivalent human papillomavirus vaccines were assumed
to provide 10, 20, or 30 years’ vaccine type protection and cross
protection or lifelong vaccine type protection without cross protection.
Three dose schedules were assumed to give lifelong vaccine type and
cross protection.
Setting United Kingdom.
Population Males and females aged 12-74 years.
Interventions No, two, or three doses of human papillomavirus vaccine
given routinely to 12 year old girls, with an initial catch-up campaign to
18 years.
Main outcome measure Costs (from the healthcare provider’s
perspective), health related utilities, and incremental cost effectiveness
ratios.
Results Giving at least two doses of vaccine seems to be highly cost
effective across the entire range of scenarios considered at the
quadrivalent vaccine list price of £86.50 (€109.23; $136.00) per dose.
If two doses give only 10 years’ protection but adding a third dose
extends this to lifetime protection, then the third dose also seems to be
cost effective at £86.50 per dose (median incremental cost effectiveness
ratio £17 000, interquartile range £11 700-£25 800). If two doses protect
for more than 20 years, then the third dose will have to be priced
substantially lower (median threshold price £31, interquartile range
£28-£35) to be cost effective. Results are similar for a bivalent vaccine
priced at £80.50 per dose and when the same scenarios are explored
by parameterising a Canadian model (HPV-ADVISE) with economic
data from the United Kingdom.
Conclusions Two dose human papillomavirus vaccine schedules are
likely to be the most cost effective option provided protection lasts for
at least 20 years. As the precise duration of two dose schedules may
not be known for decades, cohorts given two doses should be closely
monitored.
Introduction
Persistent infection with a high risk human papillomavirus type
is necessary for cervical cancer. Two human papillomavirus
vaccines are available—a bivalent vaccine with antigens for
human papillomavirus 16 and 18 associated with 70-80% of
cervical cancers globally (Cervarix) and a quadrivalent vaccine
that additionally contains antigens for human papillomavirus 6
and 11 associated withmost cases of anogenital warts (Gardasil).
Female participants receiving three doses of either vaccine in
trials were protected against persistent infection and
pre-cancerous lesions associated with human papillomavirus
16 and 18. Universal human papillomavirus vaccination of girls
before their sexual debut has been found to be cost effective in
both developed and developing countries.1 2 However, the high
cost of purchase and delivery of vaccine has been a barrier to
more widespread implementation—for example, in developing
countries and in demographic groups beyond young adolescent
girls.3 Furthermore, the need to deliver three doses of a vaccine
to a non-traditional age group can be challenging.
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Recent clinical trial and post-introduction data suggest that two
doses of human papillomavirus vaccine may be sufficient
protection for girls aged 9-14 years when administered in a
prime-boost schedule with at least six months between doses
to allow affinity maturation of memory B cells elicited by the
first dose.4 Efficacy against persistent human papillomavirus
16/18 infection in vaccinees who received two bivalent vaccine
doses was non-inferior for at least three years after vaccination
compared with those who received three doses in a post-hoc
non-randomised study in Costa Rica.5 In addition, immune
responses in 9-14 year old girls after two bivalent vaccine doses
six months apart were non-inferior for at least four years to
responses in 15-25 year old female patients receiving three
doses,6 and similar results were seen for the quadrivalent
vaccine.7 Although the Costa Rican study found no evidence of
cross protection, an exploratory analysis of a bivalent vaccine
trial suggested that antibody responses for human papillomavirus
31 and 45 in 9-14 year old girls after a two dose schedule were
comparable to those for three doses in 15-25 year olds.6As three
doses have been shown to protect against persistent infection
for almost a decade with no evidence of waning,8 9 two doses
will probably also provide long lasting protection. The European
Medicines Agency has granted marketing authorisation for two
dose schedules of both vaccines for girls below 15 years on the
basis of these data.10
Although two doses are likely to protect vaccinees for more
than a decade, whether protection (and potential cross
protection) will be as long lasting or broad as it is for three doses
is uncertain, as immunogenicity is inferior to that for three doses
in equivalent aged girls (rather than in 15-25 year olds).
Consideration of two dose schedules as an alternative to three
dose schedules relies on comparing the potential benefits of the
two dose schedule (cost savings, logistical simplicity, and
potentially higher uptake) with its risks (potentially lower
protection). As the precise duration and extent of two dose
protection is not yet known for certain, this requires
consideration of the range of possibilities that are consistent
with the available data. A cost effectiveness framework allows
an assessment of whether the economic benefits of two dose
schedules compensate for its associated risks and uncertainties.
Several jurisdictions have recently switched from three dose to
two dose vaccination schedules for girls aged 9-14 years on the
basis of such risk-benefit considerations, including Switzerland,
the Netherlands, Mexico, the United Kingdom, and Quebec. In
two jurisdictions (United Kingdom and Quebec), the decision
was explicitly made after consideration of cost effectiveness
modelling.11 12 The World Health Organization’s Strategic
Advisory Group of Experts on Immunization (SAGE) also
recommended a two dose schedule for girls aged 9-14 years
after reviewing evidence including cost effectivenessmodelling.4
Here we present a cost effectiveness analysis of two versus three
dose human papillomavirus vaccination; this analysis was used
to inform the decisions in the United Kingdom and Quebec, as
well as by SAGE to recommend a two dose schedule. The work
builds on previous modelling showing that two dose vaccination
in England and Canada can provide most of the reduction in
cervical cancer associated with three dose vaccination.13 In this
analysis, we extend the previous model to consider the full range
of human papillomavirus related diseases, including other sites
of cancer, anogenital warts, and recurrent respiratory
papillomatosis. This allows us to examine the cost effectiveness
of vaccination, particularly when the duration of protection of
two dose vaccination is assumed to be only 10 years, and hence
the difference in reduction of cervical cancer between the two
schedules is greatest (assuming no booster dose is administered
at the point of waning).
Methods
We previously constructed a model of human papillomavirus
transmission, vaccination, and screening to explore the
population level effect and cost effectiveness of various options
for three dose human papillomavirus vaccination of females in
the United Kingdom.14 15More recently, this model was adapted
to incorporate a two dose option and to explore the differential
epidemiological impact of two and three dose schedules on
incidence of cervical cancer.13
Women were assumed to undergo cytological screening, with
women aged 25-49 years screened every three years on average
and women aged 50-64 years screened every five years, as
recommended by the 2010 National Cervical Screening
Programme guidelines.16 Uptake, sensitivity, and specificity of
screening and efficacy of treatment were based on values used
in our previous analyses.17 Use of human papillomavirus DNA
testing either as triage or as the primary screen was not
incorporated.
Modelling and data analysis were conducted in C++ and R. For
this analysis, we extended our recent exploration of cervical
cancer outcomes to capture the full range of human
papillomavirus related outcomes (vulvar, vaginal, anal, penile,
and oropharyngeal cancer; anogenital warts; and recurrent
respiratory papillomatosis).13 We assumed the quadrivalent
vaccine to provide some protection against all these outcomes
and the bivalent vaccine to protect only against vulvar, vaginal,
anal, penile, and oropharyngeal cancer. Cross protection against
non-vaccine types was assumed at the level reported in a recent
meta-analysis,18 with better cross protection from the bivalent
vaccine than the quadrivalent one.
We then used all outcomes to compare healthcare costs (from
a healthcare provider’s perspective) and health related utilities
(measured in quality adjusted life years or QALYs) for different
schedules for a time horizon of 100 years. We used this to
estimate the incremental cost effectiveness of two dose schedules
(compared with no vaccination) and three dose schedules
(compared with two dose schedules). We assumed vaccination
to be given annually to 12 year old girls at 80% coverage, with
a catch-up campaign in the first year to age 18. For the two dose
schedules, we assumed girls up to age 14 to be given two doses
and girls older than this to be given three doses. We assumed
no booster doses at any age. Economic parameters and the
detailed model structure used for the cost effectiveness analysis
have been previously described.15Wedid probabilistic sensitivity
analysis by Latin hypercube sampling from the joint distribution
of the economic parameters together with 100 outcome scenarios
from the vaccine impact model that best fits pre-vaccination
epidemiological data.
Clearly, if two doses of human papillomavirus vaccine are
equivalent in every way to three doses for disease prevention,
then giving the third dose has no health or economic advantage.
To explore situations in which this is not the case, we assumed
that three dose schedules gave lifelong protection, with full
protection against cervical infection and disease due to human
papillomavirus 16/18. We estimated efficacy against human
papillomavirus 31/33/45/52/58 from a meta-analysis of
quadrivalent vaccine trials.18 We then assumed two dose
schedules either to provide reduced duration of protection (10,
20, or 30 years) or to lose efficacy against human papillomavirus
31/33/45/52/58. We assumed girls to be given quadrivalent
human papillomavirus vaccine. We then explored the predicted
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impact of two dose schedules in terms of reduction in cervical
cancer.
As the cost of vaccine procurement is unknown, we assumed a
single dose of vaccine to cost £80.50 (€101.65; $126.57) or
£86.50 (the current list price for bivalent and quadrivalent
vaccines in the United Kingdom19), with £9.33 administration
cost per dose. UK tender prices are unknown but are likely to
be substantially lower, so we also did a threshold analysis to
find the maximum price at which two dose vaccination and
three dose vaccination become cost effective. We used a
threshold of £30 000 for an intervention to be cost effective,
which is the upper limit of the threshold used by the National
Institute for Health and Care Excellence (NICE).20 All other
costs came from our previous work, but inflated to 2012-13
prices.14 15
Costs and benefits were discounted at 3.5% per annum, as
recommended in the NICE reference case.20AsNICE guidelines
also suggest that a discount rate of 1.5% per annum can be
considered for public health interventions or interventions that
have long term health benefits, we also did sensitivity analyses
using this rate.
We also explored the same scenarios about two and three dose
vaccination by using HPV-ADVISE, an individual based,
transmission dynamic model of human papillomavirus
vaccination fitted to Canadian data.21 22We retained the original
model structure and parameters governing infection transmission
and disease natural history; however, we adjusted parameters
governing cancer mortality, incidence and costs of anogenital
warts, and some utility losses associated with human
papillomavirus related disease to reflect UK data (see table 1⇓
and supplementary tables A and B for details).
Results
A two dose human papillomavirus vaccination programme is
expected to substantially decrease the incidence of human
papillomavirus related cancers and anogenital warts (fig 1⇓). If
the duration of protection of a two dose schedule is at least 20
years, then the additional benefit of the third dose is minimal,
regardless of whether the vaccine provides cross protection. A
two dose schedule giving 20 years’ protection may be sufficient
to eliminate human papillomavirus 6/11 associated anogenital
warts, so a third dose may have little or no long term benefit in
terms of protection against warts. If the duration of protection
with a two dose schedule is only 10 years, then the benefit of a
third dose in terms of reduction in all the human papillomavirus
related endpoints examined is greater, although it is still much
smaller than the benefit of the first two doses.
Similarly, the healthcare costs and QALYs saved by adding a
third dose are minimal when a two dose schedule gives at least
20 years’ protection but substantial if it gives only 10 years’
protection (fig 2⇓). Adding a third dose to a two dose schedule
with 10 years’ protection will in particular save costs associated
with cervical screening and warts.
Giving the first two doses of human papillomavirus vaccine is
clearly cost effective at a threshold of £20 000 to £30 000 per
QALY gained, regardless of the duration of protection (within
the range examined), existence of cross protection, and discount
rate. At 3.5% discounting, giving the third dose is highly
unlikely to be cost effective if the first two doses give at least
20 years’ protection. However, if the first two doses only give
10 years’ protection, and the third dose can extend this to
lifetime protection, then the third dose becomes cost effective,
with a median incremental cost effectiveness ratio of £17 000
(interquartile range £11 700-£25 800) per QALY gained (fig
3⇓ (left, solid lines) and supplementary table D). In terms of
threshold costs, the first two doses would be clearly cost
effective even if the vaccine costs £300 per dose, well above
the list price of £86.50 per dose. The third dose is cost effective
if it extends the duration of protection from 10 years to lifelong
and costs less than about £147 (£108-188) per dose (including
administration costs). However, if two doses give longer than
10 years’ protection, then in all the scenarios explored in this
model the threshold price per dose for the third dose remains
below £31 (£28-35), and may be substantially less depending
on exact assumptions about duration of protection and cross
protection (fig 4⇓ (left, solid lines) and supplementary table D).
The total costs of vaccination are shown in supplementary table
C.
Overall conclusions are also similar if a bivalent vaccine is used
instead of a quadrivalent vaccine (fig 5⇓; see supplementary
figures A and B for detailed breakdowns). Giving a third dose
is still cost effective only if it extends the duration of protection
by vaccine from 10 years to lifelong. The assumed superior
cross protection and lower vaccine cost of the bivalent vaccine
partially compensate for the loss of protection against warts and
recurrent respiratory papillomatosis. If a discount rate of 1.5%
per annum instead of 3.5% per annum is used, then the third
dose becomes slightly more cost effective, because outcomes
that occur further in the future and are prevented by having a
longer duration of protection are valued more (figures 3⇓ and
4⇓, right, solid lines). However, the overall conclusions are
unchanged.
HPV-ADVISE gives qualitatively similar results to the UK
model but is slightly more favourable to giving the third dose
(figures 3⇓ and 4⇓ (left, dashed lines) and supplementary table
E). If two dose protection lasts longer than 20 years, then the
incremental cost effectiveness ratio for giving the third dose
also lies above £30 000 per QALY gained at the list price of
£86.50 per dose. The threshold cost for the third dose of
quadrivalent vaccine to be cost effective is predicted to be £26
(£14-43), £2 (£0-7), and £26 (£15-29), respectively (including
administration costs), for the scenarios in which the first two
doses give 20 years’ duration, 30 years’ duration, and lifetime
duration but no cross protection. If the first two doses give only
10 years’ protection and the third dose gives lifetime protection,
then, like the UK model, HPV-ADVISE suggests that the third
dose is very likely to be cost effective. In this scenario, the
incremental cost effectiveness ratio of the third dose is only
£9700 (£8900-£11 000) at the vaccine list price. Results for the
bivalent vaccine are similar, with the third dose again being
cost effective only if it extends protection from 10 years to
lifetime.
Discussion
If the quadrivalent human papillomavirus vaccine costs £86.50
per dose or less to procure and distribute, then giving 12 year
old girls at least two doses of vaccine is clearly cost effective.
However, the cost effectiveness of giving the third dose of
vaccine is highly dependent on how well the first two doses
protect. If two doses protect for only 10 years but adding a third
dose extends this to lifetime protection, then the third dose may
be cost effective even if giving a dose of vaccine costs £86.50
or more. Conversely, if two doses protect for 20 years or more,
or if they give lifetime protection against vaccine type disease
but without cross protection, then the third dose has to be
substantially cheaper than its list price to be cost effective.
Overall conclusions are the same for the bivalent vaccine,
although the cost effectiveness of two versus three dose
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schedules differs slightly owing to differing cross protection
and protection against warts. Also, evidence about the efficacy
and immunogenicity of two doses of each of the two vaccines
is not equivalent. For example, no clinical efficacy data using
two doses of the quadrivalent vaccine is available.
The same conclusions hold when equivalent scenarios are
explored using HPV-ADVISE fitted to Canadian data on human
papillomavirus epidemiology and sexual mixing, but using
economic parameters from the United Kingdom. HPV-ADVISE
is slightly more favourable to three dose vaccination compared
with results from the UK model, particularly when two doses
of human papillomavirus vaccine provide only 10 years of
protection. The reasons for this have been previously explored13;
they are likely to be differences between self reported rates of
change of sexual partner in UK and Canadian women beyond
the 20-25 year old age group (when they would no longer be
protected by a two dose vaccine giving only 10 years’
protection), as well as the way this is represented in the two
models.
Strengths and limitations
Both the UK model and HPV-ADVISE are transmission
dynamic models that take into account indirect (herd) vaccine
protection due to reduced transmission of human papillomavirus.
Herd protection is likely to be a substantial contributor to the
impact of two dose programmes with less than lifetime duration
of protection. Models also incorporate the full range of human
papillomavirus related outcomes, including cervical cancer (and
its precursors), other cancers, and anogenital warts. The
consistency of results between the two models despite
differences in underlying human papillomavirus epidemiology
represented in each of them suggests that the main conclusions
are generalisable to other high income countries with similar
human papillomavirus epidemiology. However, caution is
needed in interpreting the results for resource poor settings
owing to differences in sexual behaviour, human papillomavirus
epidemiology, cervical screening coverage, and healthcare costs.
Similar analyses for these settings are a priority, particularly
following the Strategic Advisory Group of Experts on
Immunization’s global recommendation of two dose schedules.
One limitation of this analysis is that it does not capture
historical changes in the human papillomavirus vaccination
programme in the United Kingdom over the past six years. This
includes the introduction of bivalent human papillomavirus in
2008 with a catch-up campaign staggered over two years, a
switch to the quadrivalent vaccine in 2011, and a switch from
three dose to two dose vaccination in September 2014. Instead,
we considered a more general scenario in which quadrivalent
vaccination is introduced with either two or three doses from
the start of the programme, and with a catch-up programme up
to age 18 years. This allows results to be more readily
generalised to other settings where human papillomavirus
vaccination may be (or has already been) introduced with a
different configuration from the United Kingdom. Furthermore,
it is a conservative assumption: assuming that the same schedule
(two or three dose) is followed from the start of the programme
maximises the difference in impact between the two schedules.
Conversely, allowing a few years of three dose vaccination will
temporarily reduce any potential loss of effectiveness when
switching to two doses because of residual herd protection from
older vaccinees who have received three doses.
Our model assumed that cervical screening is cytology based.
Several countries (such as the Netherlands and Italy) have
moved from cytology based to human papillomavirus DNA
based detection methods as their primary cervical screening
method.23 In the United Kingdom, cytology is still used as the
primary test, although human papillomavirus DNA testing as
primary has been piloted in several areas.24 However, countries
that have moved to a primary human papillomavirus DNA
testing algorithm have been conservative in the move, in that
they have chosen an algorithm such that the lifetime risk of
cancer in women screened using primary human papillomavirus
DNA testing is predicted to be no greater than it was using the
former primary cytology based algorithm. Consequently, any
change to human papillomavirus testing can only decrease (or
leave unchanged) the benefit of giving a third dose of vaccine,
as there will be fewer (or the same number of) cancers to
prevent. Hence the overall conclusions about giving a third dose
not being cost effective if two doses provide at least 20 years’
protection would still hold.
Implications and future research
In the United Kingdom and many other countries with
competitive tendering, tender prices for vaccines can be
substantially lower than their list price. If two doses give only
20 years’ protection, then the threshold price for the third dose
to be cost effective is around £16 with 3.5% discounting or £32
with 1.5% discounting, which may still be within the realms of
possibility for the tender price of human papillomavirus
vaccines, particularly as vaccine prices mature in the future.
However, if 30 years’ protection and cross protection can be
expected from two doses, then the third dose will be cost
effective only if it can be purchased and delivered for less than
£3 a dose (with 3.5% discounting), which is below the current
administration cost for human papillomavirus vaccines in the
United Kingdom.15
Protection from two doses is likely to be long lasting, but
whether it will be as long lasting or broad as it is for three doses
is uncertain. There may be no way to determine a priori whether
duration of protection from two doses will exceed 30 years.
Consequently, dropping the third dose of human papillomavirus
vaccine carries a risk as the outcomes relative to retaining three
doses are uncertain. This uncertainty cannot be eliminated by
modelling. However, economic modelling allows quantification
of the relative value of different strategies in terms of their health
and economic benefits given their possible outcomes, so that
an informed decision about dosage can be made on the basis of
weighing risks and benefits. Results of the model also support
close monitoring of cohorts given two doses of human
papillomavirus vaccines, with the possibility of booster doses
or even increasing the number of doses for adolescents if waning
is detected decades in the future.
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What is already known on this topic
Two dose human papillomavirus vaccine schedules are likely to provide long lasting protection against human papillomavirus 16 and
18
The exact duration and breadth of two dose protection compared with three dose protection is uncertain
What this study adds
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this to lifetime protection, then the third dose also seems likely to be cost effective
If two doses provide more than 20 years’ protection, then they are likely to be the most cost effective option
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Table
Table 1| Cost and quality of life parameters used by UK model and HPV-ADVISE
Mean (95% uncertainty interval)
Parameter HPV-ADVISEUK model
Treatment costs
£16 200£16 400 (4360 to 43 700)*Cervical cancer
£12 200£14 900 (3770 to 40 800)*Vulvar-vaginal cancer
£10 400£14 300 (3300 to 40 800)*Anal cancer
£16 400£16 300 (4270 to 43 400)*Oropharyngeal cancer
£10 900£12 700 (3340 to 34 200)*Penile cancer
£121£121 (112 to 130)*Anogenital warts
Recurrent respiratory papillomatoses:
Not modelled£32 300 (1100 to 178 000)*Juvenile
Not modelled£5300 (621 to 20 500)*Adult
Screening costs
£58£58 (30 to 87)*Cytology (liquid based)
£156£156 (80 to 232)*Colposcopy
£378£378 (193 to 562)*Pre-cancerous lesion treatment
Vaccine costs (per dose)
£86.50£86.50†Quadrivalent vaccine
£80.50£80.50†Bivalent vaccine
£9.33£9.33‡Administration
Quality of life weights
0.30 (stage I-III) or 0.38 (stage IV)0.285 (0.25 to 0.32)*Cervical cancer treatment
0.320.32 (0.19 to 0.47)*Vulvar-vaginal cancer treatment
0.510.51 (0.28 to 0.76)*Anal cancer treatment
0.250.25 (0.21 to 0.29)*Oropharyngeal cancer treatment
0.290.29 (0.22 to 0.36)*Penile cancer treatment
Not modelled0.0305 (0.00682 to 0.0542)*Recovery from cancer
QALY loss per episode
Not modelled0.025 (0.013 to 0.037)*Positive cytology result
0.0060.012 (0.006 to 0.018)*Positive CIN1 result
0.010.007 (0.004 to 0.010)*Positive CIN2 result
0.010.054 (0.027 to 0.080)*Positive CIN3 result
0.0180.018 (0.007 to 0.030)*Episode of anogenital warts
Not modelled1.3 (0.13 to 5.3)*Episode of recurrent respiratory papillomatosis
CIN=cervical intra-epithelial neoplasia; QALY=quality adjusted life year.
For UK model, figures show means and 2.5% to 97.5% centiles of distributions representing uncertainty in corresponding parameter values; some parameters do
not match exactly across two models because they are functions of other parameters that are estimated in different ways (see supplementary table B for actual
distributions).
*From Jit et al (2011),16 inflated to 2012/13 prices.
†From British National Formulary 65 (March 2013).
‡From Jit et al (2011).16
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Figures
Fig 1 Estimated annual number of cases of cervical cancer, other human papillomavirus related cancers, and vaccine
human papillomavirus type warts 100 years after vaccination given no vaccine, two dose quadrivalent vaccination with
different characteristics, and three dose vaccination. Results are medians and interquartile ranges of 1000 Latin hypercube
samples
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;350:g7584 doi: 10.1136/bmj.g7584 (Published 7 January 2015) Page 7 of 10
RESEARCH
Fig 2 Incremental healthcare costs and quality adjusted life years (QALYs) saved, discounted at 3.5% or 1.5% per annum,
over 100 years of two dose quadrivalent vaccination (compared with no vaccination) and three dose vaccination (compared
with two dose vaccination). Results are medians of 1000 Latin hypercube samples
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Fig 3 Incremental cost per quality adjusted life year (QALY) gained for two dose quadrivalent vaccination (compared with
no vaccination; on logarithmic scale) and three dose quadrivalent vaccination (compared with two dose vaccination). Results
are medians and interquartile ranges of 1000 Latin hypercube samples. Results using HPV-ADVISE are shown with dotted
bars for comparison. One vaccine dose was assumed to cost £86.50 for procurement and £9.33 for administration. Discount
rate is 3.5% (left) or 1.5% (right) per annum. Shaded area is £20 000-£30 000 per QALY gained
Fig 4 Maximum price per dose (including administration costs) at which two dose quadrivalent vaccination (compared with
no vaccination) and three dose quadrivalent vaccination (compared with two dose vaccination) become cost effective,
based on threshold of £30 000 for intervention to be cost effective. Results are medians (given in corresponding text) and
interquartile ranges of 1000 Latin hypercube samples. Results using HPV-ADVISE are shown with dotted bars for comparison.
Discount rate is 3.5% (left) or 1.5% (right) per annum
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Fig 5 Incremental cost per quality adjusted life year (QALY) and maximum price per dose (including administration costs)
at which bivalent vaccination becomes cost effective. One vaccine dose was assumed to cost £86.50 for procurement and
£9.33 for administration. Discount rate is 3.5%. Shaded area is £20 000-£30 000 per QALY gained
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